CD28 in the tumor microenvironment. From Nat Rev Immunol. 2024.
Recent clinical success stories in immunotherapy (checkpoint inhibitors, CAR T cells, bispecific antibodies, etc.) commonly rely on inducing a cytotoxic T cell response against tumor cells, yet many of the molecular details of how these therapies work on T cells remain unknown.
Over the past several years, the Olejniczak Lab has made extensive use of chimeric antigen receptor (CAR) transduced T cells, focusing on T cell co-receptor signaling.
We currently have projects aimed at improving CAR T cell therapy for multiple myeloma and pediatric sarcoma, as well as projects aimed at improving checkpoint inhibitor therapy for melanoma and lung cancer.
Facilitated by intra-disciplinary, intra-programmatic collaborations at Roswell Park, we hope to positively influence clinical practice and bring new immunotherapeutic options to cancer patients desperately in need of better and safer therapies.
Connect with the Olejniczak Lab
Email Dr. OlejniczakConnect on LinkedIn
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263